Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Cash (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Change in Cash for 16 consecutive years, with $3.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash rose 1793.07% to $3.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $24.5 million, a 340.24% increase, with the full-year FY2024 number at -$21.7 million, down 360.33% from a year prior.
  • Change in Cash was $3.9 million for Q3 2025 at Gyre Therapeutics, down from $21.4 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $52.7 million in Q1 2021 to a low of -$52.3 million in Q3 2022.
  • A 5-year average of $343842.1 and a median of -$1.4 million in 2022 define the central range for Change in Cash.
  • Peak YoY movement for Change in Cash: crashed 372.39% in 2021, then skyrocketed 1793.07% in 2025.
  • Gyre Therapeutics' Change in Cash stood at -$14.8 million in 2021, then surged by 90.38% to -$1.4 million in 2022, then soared by 621.77% to $7.4 million in 2023, then plummeted by 154.55% to -$4.1 million in 2024, then surged by 196.5% to $3.9 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Change in Cash are $3.9 million (Q3 2025), $21.4 million (Q2 2025), and $3.2 million (Q1 2025).